Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
复制标题
DOI：
10.1038/modpathol.3800528
复制
发表时间：
2006-02-01
期刊：
影响因子：
7.5
通讯作者：
Perou, CM
中科院分区：
文献类型：
--
作者：
Livasy, CA;Karaca, G;Perou, CM
浸润性乳腺癌的微阵列分析已经确定了与不同临床结果相关的五种不同的肿瘤亚型（管腔A型、管腔B型、正常乳腺样、HER 2过表达和基底样）。基底样亚型与不良临床结局相关，是BRCA 1相关乳腺癌中观察到的亚型。本研究的目的是描述乳腺基底细胞样癌的组织学和免疫表型特征，这些癌是首次使用DNA微阵列分析确定的。对56例具有已知微阵列特征的肿瘤（23例基底样，23例管腔，12例HER 2+）进行了详细的组织学检查。对18例基底细胞样肿瘤、16例管腔型肿瘤和12例HER 2+肿瘤进行了雌激素受体（ER）、HER 2、EGFR、平滑肌肌动蛋白（SMA）、p63、CD 10、细胞角蛋白5/6、细胞角蛋白8/18和波形蛋白的免疫组织化学。基底样肿瘤为3级导管/NOS（21/23）或化生性（2/23）癌，经常显示地图状坏死（17/23）、浸润推进边界（14/23）和间质淋巴细胞反应（13/23）。大多数基底细胞样肿瘤表达波形蛋白（17/18）、腔细胞角蛋白8/18（15/18）、EGFR（13/18）和细胞角蛋白5/6（11/18），而肌上皮标志物SMA（4/18）、p63（4/18）和CD 10（2/18）的阳性率较低。所有检测的基底细胞样肿瘤均为ER-和HER 2-。与基底细胞样亚型显著相关的形态学特征包括核分裂计数显著升高（P
Microarray profiling of invasive breast carcinomas has identified five distinct subtypes of tumors ( luminal A, luminal B, normal breast-like, HER2 overexpressing, and basal-like) that are associated with different clinical outcomes. The basal-like subtype is associated with poor clinical outcomes and is the subtype observed in BRCA1-related breast cancers. The aim of this study was to characterize the histologic and immunophenotypic properties of breast basal-like carcinomas that were first positively identified using DNA microarray analysis. Detailed histologic review was performed on 56 tumors with known microarray profiles ( 23 basal-like, 23 luminal, and 12 HER2+). Immunohistochemistry for estrogen receptor ( ER), HER2, EGFR, smooth muscle actin (SMA), p63, CD10, cytokeratin 5/6, cytokeratin 8/18, and vimentin was performed on 18 basal-like, 16 luminal, and 12 HER2+ tumors. The basal-like tumors were grade 3 ductal/NOS (21/23) or metaplastic (2/23) carcinomas that frequently showed geographic necrosis (17/23), a pushing border of invasion (14/23), and a stromal lymphocytic response ( 13/23). Most basal-like tumors showed immunoreactivity for vimentin (17/18), luminal cytokeratin 8/18 (15/18), EGFR (13/18), and cytokeratin 5/6 (11/18), while positivity for the myoepithelial markers SMA (4/18), p63 ( 4/18) and CD10 (2/18) was infrequent. All basal-like tumors tested were ER- and HER2-. Morphologic features significantly associated with the basal-like subtype included markedly elevated mitotic count (P